Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:NUVB
NYSE:NUVBPharmaceuticals

How Investors May Respond To Nuvation Bio (NUVB) EMA Review Of Taletrectinib Milestone Opportunity

Nuvation Bio recently reported that the European Medicines Agency validated its Marketing Authorization Application for taletrectinib (IBTROZI) to treat advanced ROS1-positive non-small cell lung cancer, starting a formal review process that could eventually unlock US$30,000,000 in milestone payments from partner Eisai if approval in the European Union is granted. This regulatory progress in Europe adds a fresh potential revenue stream and external validation for Nuvation Bio’s oncology...
NYSE:BLK
NYSE:BLKCapital Markets

A Look At BlackRock (BLK) Valuation As It Prepares To Launch New Nasdaq 100 ETF IQQ

BlackRock (BLK) is preparing to launch the iShares Nasdaq 100 ETF, ticker IQQ. The fund will offer direct exposure to the tech heavy index at a time when investors already have several growth focused ETFs. See our latest analysis for BlackRock. Recent headlines around the IQQ filing and changes to BlackRock's revolving credit facility come as the stock trades at US$999.31, with a 30 day share price return of 5.06%, a year to date share price return decline of 7.90%, and a 1 year total...
NYSE:CR
NYSE:CRMachinery

Assessing Crane (CR) Valuation After Technical Breakout And Sector Tailwinds

Technical breakout puts Crane in focus Crane (CR) is back on traders’ radar after an afternoon push above its month moving average, with the share price pressing against the upper Bollinger Band on rising volume. See our latest analysis for Crane. The breakout sits against a mixed backdrop, with a 12.18% 7 day share price return and a 6.96% 90 day share price decline, while a 1 year total shareholder return of 34.44% points to longer term momentum. If Crane’s move has you looking for other...
NasdaqGS:SLP
NasdaqGS:SLPHealthcare Services

Simulations Plus (SLP) Quarterly Profit Tests Bearish Narratives On Earnings Decline

Simulations Plus (SLP) has put up a mixed Q2 2026 scorecard, with revenue of about US$24.3 million and basic EPS of roughly US$0.22, alongside trailing twelve month figures that show total revenue of about US$80.5 million and a basic EPS loss of roughly US$3.12. Over recent quarters, revenue has ranged from about US$17.5 million to US$24.3 million while quarterly basic EPS has swung between a loss of about US$3.35 and a profit of roughly US$0.22. This leaves investors focused squarely on how...
TSX:CSU
TSX:CSUSoftware

Is It Time To Reassess Constellation Software (TSX:CSU) After A 49% Share Price Slide?

Before looking at models and ratios, the key question is whether Constellation Software's current share price still reflects its quality or if recent weakness has created a potential opportunity for you. Over the last year, the stock has fallen 49.5%, with a 29.1% decline year to date, including 15.0% over the past month and 6.0% over the last week. This may signal shifting expectations and a different balance between risk and potential reward than many investors were pricing in...
NasdaqGS:HTO
NasdaqGS:HTOWater Utilities

Is It Too Late To Consider H2O America (HTO) After Recent Share Price Gains?

Wondering if H2O America at around US$59.67 still offers value or if most of the upside is already priced in? This article breaks down what the current share price might be telling you. The stock has returned 0.8% over the last 7 days, 6.2% over 30 days, 21.2% year to date, and 15.5% over 1 year, while the 3 year and 5 year returns sit at a 17.8% decline and roughly flat respectively. These mixed returns suggest shifting market expectations over time, with more recent performance looking...
NasdaqGS:ROKU
NasdaqGS:ROKUEntertainment

What Roku (ROKU)'s New Free Channels and Features Expansion Means For Shareholders

Roku recently broadened The Roku Channel’s free offering by adding six ad-supported channels spanning Westerns, classic sitcoms, reality competitions, comedy, and Spanish-language music, while also rolling out features like Instant Resume across high-traffic apps. Alongside these additions, Roku’s collaboration with Amazon Prime on the new Howdy subscription service and exclusive content such as the Laguna Beach reunion special highlight how the company is using a mix of free and premium...
NYSE:HRI
NYSE:HRITrade Distributors

Assessing Herc Holdings (HRI) Valuation After Sector Momentum Lifts Rental And Leasing Stocks

Sector momentum puts Herc Holdings (HRI) back in focus Herc Holdings (HRI) has moved higher amid a sector wide upswing in rental and leasing, as traders respond to growing interest in owner managed platforms and adjust their positioning around potential market share shifts. See our latest analysis for Herc Holdings. At a share price of US$102.96, Herc has seen a sharp 7 day share price return of 13.09% after a longer stretch of weaker performance, including a 90 day share price return decline...
NYSE:DOV
NYSE:DOVMachinery

Dover’s SteelXL CO2 Heat Pump Adds Weight To Decarbonization Story

Dover’s Advansor division has introduced the SteelXL Heat Pump, a large capacity CO2 heat pump for industrial and commercial use. The system targets applications such as food processing facilities and district heating networks that are seeking alternatives to gas and oil boilers. The launch expands NYSE:DOV’s offering in sustainable heating solutions that align with decarbonization and regulatory trends in HVAC. For NYSE:DOV, the SteelXL Heat Pump adds to its presence in industrial...
NasdaqGS:SATS
NasdaqGS:SATSMedia

EchoStar Launches Sling Essentials As Investors Weigh Valuation And Momentum

EchoStar's Sling TV unit has launched Sling Essentials, a new low-cost national live TV service with key sports and entertainment channels. The bundle targets cost conscious cord cutters seeking live sports and popular networks at a lower price point. EchoStar, listed as NasdaqGS:SATS, is rolling out Sling Essentials while its share price stands at $128.59. The stock has very large 1 year and 3 year returns, and the 5 year move is also very large, which puts extra attention on how new...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

Axsome Therapeutics (AXSM) Is Up 6.2% After Highlighting Key FDA Decision on Auvelity

Axsome Therapeutics recently highlighted the upcoming release of its first-quarter 2026 results on May 4 and the pending US Food and Drug Administration decision on Auvelity for agitation associated with Alzheimer's disease, a potential new indication for its central nervous system portfolio. Analysts see the Alzheimer's agitation application for Auvelity as a potentially meaningful new revenue stream, given the high unmet medical need and expectations that the drug may avoid an added...
ENXTLS:EDP
ENXTLS:EDPElectric Utilities

Assessing EDP’s Valuation After Spain’s First Solar And Battery PPA With Zelestra

EDP (ENXTLS:EDP) drew investor attention after partnering with Zelestra on Spain’s first power purchase agreement to hybridise an existing solar plant in Cáceres with a 160 MWh battery energy storage system. See our latest analysis for EDP. At a share price of €4.735, EDP has a 30 day share price return of 9.78% and a 90 day share price return of 15.69%, while the 1 year total shareholder return of 64.02% reflects recent momentum around its renewables and grid projects. If this kind of clean...
NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

Is Rhythm Pharmaceuticals (RYTM) Still Attractive After A 48.9% One‑Year Share Price Gain

Wondering whether Rhythm Pharmaceuticals at US$86.13 still makes sense for your portfolio, or if the recent price leaves little margin for value? The stock has pulled back by 0.2% over the last week and 7.4% over the last month, while the 1‑year return sits at 48.9% and the 5‑year return at 315.3%. Recent coverage has focused on Rhythm Pharmaceuticals as a specialist in rare genetic disorders, with attention on how its approved therapy and commercial rollout are shaping expectations...
NYSE:CF
NYSE:CFChemicals

A Look At CF Industries (CF) Valuation After Ceasefire News Cools Fertilizer Supply Fears

CF Industries Holdings (CF) is back in focus after news of a U.S.–Iran ceasefire cooled expectations of prolonged fertilizer supply constraints, triggering a pullback that followed an earlier rally tied to Persian Gulf disruptions. See our latest analysis for CF Industries Holdings. The ceasefire headlines triggered a sharp reset in expectations, but CF Industries’ recent 46.88% 3 month share price return and 72.42% 1 year total shareholder return still point to strong momentum that has built...
NYSE:UPS
NYSE:UPSLogistics

Ceasefire Eases Fuel Costs And Reshapes The UPS Profit Story

A ceasefire in the Strait of Hormuz is allowing vessels to pass more freely, easing recent disruptions in oil flows. Crude oil prices have pulled back, reducing fuel costs for global shippers including United Parcel Service (NYSE:UPS). Lower fuel expenses improve UPS's operating environment and may support stronger profit margins versus the recent conflict period. For United Parcel Service, the shift in fuel costs comes at a time when the stock has shown mixed performance, with a 3.6% gain...
NYSE:CALX
NYSE:CALXCommunications

Does Calix’s Governance Stance and BBT Traction Shift the Bull Case for CALX?

In March 2026, Calix, Inc. filed a definitive proxy statement urging shareholders to vote against a proposal to replace supermajority voting thresholds with simple majority requirements in its charter and bylaws. Separately, broadband provider BBT reported strong year-over-year ARPU growth and rapid rollout of Calix-powered small business services, underlining tangible customer momentum for Calix’s platform. With BBT’s ARPU gains tied to Calix One and SmartBiz, we’ll examine how this...
NYSE:CAAP
NYSE:CAAPInfrastructure

Is It Too Late To Consider Corporación América Airports (NYSE:CAAP) After Its Multi‑Year Surge?

Wondering if Corporación América Airports at US$27.07 is priced for its future potential or already reflects the story you care about? This article focuses squarely on what you are paying versus what you might be getting. The stock has seen a 5.5% return over the last 7 days, 4.9% over the last month, 1.9% year to date, 56.0% over the last year and a very large gain over 3 and 5 years. This naturally raises questions about how much of that performance is already baked into the current...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

Does New Epidiolex Behavioral Data at AAN 2026 Reframe Jazz Pharmaceuticals’ (JAZZ) Neuroscience Strategy?

Jazz Pharmaceuticals recently announced it will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology Annual Meeting, sharing new clinical data on Epidiolex for rare epilepsies and Xywav for narcolepsy. A key update is the 6‑month EpiCom analysis showing reduced caregiver‑ and clinician‑reported behavioral problems in patients with tuberous sclerosis complex–associated seizures after starting Epidiolex, underlining the drug’s potential impact...
NYSE:DOCN
NYSE:DOCNIT

Is It Too Late To Consider DigitalOcean Holdings (DOCN) After Its 173.5% One Year Rally?

Wondering whether DigitalOcean Holdings at around US$75.59 is still priced for opportunity or already reflects the story you are buying into today? This article walks through the numbers so you can judge how the current price lines up with the underlying business. The stock has seen a 16.0% decline over the last 7 days, a 10.0% gain over 30 days, is up 54.4% year to date and has returned 173.5% over the past year, which can change how risk and reward feel at today's level. Recent coverage...